Excalibur To Test AZ Compound In Diabetics With COVID-19
Potential Benefits Include Reduced Incidence Of ARDS
Executive Summary
A randomized double-blind study will look at whether a glucokinase activator in addition to usual care can help improve clinical outcomes in type 1 and 2 diabetes patients with coronavirus symptoms.